New Onset Depressive Symptoms in Acute Illness (R21 Clinical Trial Not Allowed) | PA 17 487

Opportunity Information: Apply for PA 17 487

The National Institutes of Health (NIH) funding opportunity titled "New Onset Depressive Symptoms in Acute Illness (R21 Clinical Trial Not Allowed)" (Funding Opportunity Number PA-17-487) supports exploratory research aimed at understanding why depressive symptoms can newly emerge during or after a sudden acute medical illness. The central focus is on etiology and pathobiology: identifying the biological, psychological, and contextual mechanisms that help explain incident depressive symptoms that arise in the setting of an acute health event, even when the physical illness itself appears to resolve. The NIH highlights a key gap in the field: while it is well recognized that depressive symptoms can persist and interfere with functional recovery long after the acute medical insult, there remains limited knowledge about the underlying drivers of these symptoms, including how acute illness may trigger or accelerate depressive processes. By improving understanding of these mechanisms, the program aims to lay groundwork for more personalized and holistic approaches to recovery that address both physical and mental health trajectories.

This opportunity uses the R21 grant mechanism, which is generally designed for early-stage, high-risk/high-reward, and concept-developing projects. In practical terms, that means the NIH is encouraging innovative studies that may generate preliminary data, test new ideas, or open up emerging lines of inquiry rather than requiring a fully mature, large-scale research program. The FOA explicitly states that clinical trials are not allowed, so proposed projects should not involve assigning human participants to interventions to evaluate health-related outcomes. Instead, applicants would typically consider observational studies, mechanistic investigations, analyses of existing datasets or biospecimens, development or validation of measures relevant to post-acute depressive symptoms, or other non-interventional designs that can advance causal or mechanistic understanding without constituting a clinical trial.

The research scope implied by the FOA centers on acute illness as the initiating context, with attention to depressive symptoms that are new in onset rather than simply ongoing depression that predates the illness. The NIH interest includes clarifying factors that contribute to a sustained symptom trajectory versus those that mitigate risk and support resilience. This can include, for example, biological responses to acute insults (such as inflammation, neuroendocrine stress responses, immune signaling, metabolic disruption, sleep-wake disturbances, pain physiology, or neurovascular effects), as well as psychological and environmental contributors (such as acute stress, trauma-like responses to hospitalization, delirium-related experiences, social isolation, functional impairment, and barriers to rehabilitation). The broader goal is to connect these etiologic factors to recovery outcomes, since lingering depressive symptoms can slow return to work or school, reduce adherence to follow-up care, worsen perceived quality of life, and impair physical rehabilitation even when the primary medical condition improves.

From an administrative standpoint, this is a discretionary grant program under NIH, categorized within education and health-related funding activity areas and associated with CFDA numbers 93.242 and 93.361. The listed award ceiling is $200,000, indicating the maximum amount available under the terms provided in the source data. The FOA record shows an original closing date of January 7, 2021, and a creation date of September 19, 2017. (Programs like this sometimes have multiple receipt dates or get reissued under new announcements, but the provided listing reflects the specific record and dates supplied.)

Eligibility is broad and includes a wide range of public, private, academic, nonprofit, tribal, and governmental entities. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments (federally recognized); public housing authorities/Indian housing authorities; Native American tribal organizations (other than federally recognized tribal governments); nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The announcement also explicitly notes additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and even non-U.S. entities (foreign organizations), as well as Indian/Native American tribal governments that are not federally recognized.

Overall, this FOA is aimed at pushing the science of post-acute mental health beyond simple documentation of depression after illness and toward a clearer, mechanism-based understanding of why new depressive symptoms occur, which patients are most vulnerable, and what protective factors may alter the course. The expected payoff is a stronger evidence base to inform future screening strategies, risk stratification, and integrated recovery models that treat mental health symptoms as a core component of acute illness recovery rather than an afterthought.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "New Onset Depressive Symptoms in Acute Illness (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.361.
• This funding opportunity was created on 2017-09-19.
• Applicants must submit their applications by 2021-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $200,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 17 487

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: